By Connor Hart

Indivior reached a settlement with the state of New York and will cease all promotion of Opvee, its opioid overdose drug.

The New York attorney general's office said Tuesday that the pharmaceutical company marketed the drug to public officials throughout the state, promoting it as an alternative to the overdose reversal medication naloxone, sometimes known by the brand name Narcan.

Indivior did so, the office alleged, despite knowing that Opvee is not authorized by the state's Department of Health for use without a prescription. The company didn't immediately respond to a request for comment.

Under the settlement, Indivior agreed to refund taxpayer dollars it received for Opvee, recall improperly sold doses, stop making false statements about the drug and implement broad reforms to its marketing and training practices, legal documents show.

Indivior has since told stakeholders it will discontinue promotion of Opvee altogether, the office said.

"Indivior cannot rewrite its history and exploit this drug crisis for profit," Attorney General Letitia James said. "After playing a role in fueling the opioid epidemic, the company tried to position itself as part of the solution while misleading public officials and the communities they serve about which overdose treatments are safe, legal and effective."

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

September 30, 2025 11:04 ET (15:04 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.